|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 胆固醇酯转移蛋白基因的蛋白质截断型变异体与冠状动脉性心脏病风险的关系显示文摘随机对照试验结果表明,抑制胆固醇酯转运蛋白(cholesteryl ester transfer protein,CETP)的疗法并不能降低冠状动脉性心脏病(coronary heart disease,CHD)的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应和随机对照设计因素影响等。在编码药物靶点的基因中具有天然存在的遗传变异,以此为基础,人类研究可以深入了解针对基因产物的治疗的潜在功效和安全性。 | Nomura A Won HH Khera AV Takeuchi F Ito K McCarthy S Emdin CA Klarin D Natarajan P Zekavat SM Gupta N Peloso GM Borecki IB Teslovich TM Asselta R Duga S Merlini PA Correa A Kessler T Wilson JG Bown MJ Hall AS Braund PS Carey DJ Murray MF Kirchner HL Leader JB Lavage DR Manus JN Hartze DN Samani NJ Schunkert H Marrugat J Elosua R McPherson R Farrall M Watkins H Juang JJ Hsiung CA Lin SY Wang JS Tada H Kawashiri MA Inazu A Yamagishi M Katsuya T Nakashima E Nakatochi M Yamamoto K Yokota M Momozawa Y Rotter JI Lander ES Rader DJ Danesh J Ardissino D Gabriel S Willer CJ Abecasis GR Saleheen D Kubo M Kato N Ida Chen YD Dewey FE Kathiresan S 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，9： | 2 |
| 2 | Clinical pathways : effects on professional practice, patient outcomes, length of stay and hospital costs显示文摘 | Rotter T Koch R Kugler J | 2007 | Cochrane Database Syst Rev2007，17，3： | 1 |
| 3 | The effects ofclinical pathways onprofessional practice, patient outcomes, length of stay andhospital costs: Cochrane systematic review and meta-analysis显示文摘 | Rotter T Kinsman L James E | 2012 | Evaluati0n &theHealth Professions2012，35，1： | 1 |
| 4 | What is a clinical pathway? Development of a definition to inform the debate显示文摘 | Kinsman L Rotter T James E | 2010 | BMC medi- cine2010，8，1： | 1 |
| 5 | Clinical pathways:effects on professional practice,patient outcomes,length of stay and hospital costs显示文摘 | Rotter T Koch R Kugler J | 2007 | Cochrane Database Syst Rev2007，3，： | 1 |
| 6 | The effects of clinical pathways on professional practice, patient outcomes ,length of stay, and hospital costs: cochrane systematic review and meta-analysis 显示文摘 | ROTTER T KINSMAN L JAMES E | 2012 | Eval Health Prof2012，35，1： | 1 |
| 7 | A systematic review and meta - anal- ysis of the effects of clinical pathways on length of stay,hospital costs and patient outcomes显示文摘 | Rotter T Kugler J Koch R | 2008 | BMC Health Serv Res2008，8，： | 1 |
| 8 | The effects of clinical pathways on professional practice,patient outcomes,length of stay,and hospital costs:Cochrane systematic review and meta-analysis显示文摘 | Rotter T Kinsman L James E | 2012 | Eval Health Prof2012，35，1： | 1 |
| 9 | High-density activation mapping of fractionated electrograms in the atria of patients with paroxysmal atrial fibrillation显示文摘 | Rostock T Rotter M Sanders P | 2006 | Heart Rhythm2006，3，： | 1 |
| 10 | The effects of clinical path- ways on professional practice, patient outcomes, length of stay, and hospital costs: Cochrane systematic review and meta-analysis 显示文摘 | Rotter T Kinsman L James E | 2012 | Eval Health Prof2012，35，1： | 1 |
| 11 | What is a clinical pathway?Development of a definition to inform the debate显示文摘 | Kinsman L Rotter T James E | 2010 | BMA Med2010，8，5： | 1 |
| 12 | Clinical pathways:effects on professional practice? patient outcomes, lengthof stay and hospital costs 显示文摘 | Rotter T Kinsman L James E | 2010 | Cochrane Database SystRev2010，，00： | 1 |
| 13 | The effects of clini-cal pathways on professional practice, patient outcomes,length of stay,and hospital costs:Cochrane systematic re-view and meta-analysis 显示文摘 | Rotter T Kinsman L James E | 2012 | Eval Health Prof2012，35，1： | 1 |
| 14 | A systematic review and metaanalysis of the effects of clinical pathway soil length of stay,hospi-tal costs and patient outcomes显示文摘 | Rotter T Kugler J Koch R | 2008 | BMC Health Serv Res2008，19，8： | 1 |
| 15 | The Effects of Clinical Pathways on Professional Practice, Patient Outcomes, Length of Stay, and HosPital Costs Cochrane Systematic Review and Meta- Analysis 显示文摘 | Rotter T Kinsman L James E | 2012 | Evaluation & the health Professions2012，35，1： | 1 |
| 16 | What is a clinical pathway? Development of a definition to inform the debate显示文摘 | Kinsman L Rotter T James E | 2010 | BMC medi- cine2010，8，1： | 1 |
| 17 | High-density activation mapping of fractionated electrograms in the atria of patients with paroxysmal atrial fibrillation显示文摘 | Rostock T Rotter M Sanders P | 2006 | Heart Rhythm2006，3，1： | 1 |
| 18 | What is a clinical pathway? Devel- opment of a definition to inform the debate显示文摘 | Kinsman L Rotter T James E | 2010 | BMC Med2010，27，： | 1 |
| 19 | Evolution of novel O-methyltransferases from the Vanilla planifolia caffeic acid O-methyltransferase 显示文摘 | Li H M Rotter D Hartman T C | 2006 | Plant Mol Biol2006，61，： | 1 |
| 20 | The quality of the evidence basefor clinical pathway effectiveness : room for improvement in the designof evaluation trials显示文摘 | Rotter T Kinsman L James E | 2012 | BMC Med Res Methodol2012，12，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员